Intelligence · Clinical Development
Pipeline search results
Programs matching “asthma” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 226 pipeline programs matching "asthma" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
AROMUC5AC-1001
Arrowhead Pharmaceuticals Ireland Limited
Asthma and Chronic obstructive pulmonary disease
1 trial -
ARS-1
Ars Pharmaceuticals Irl Limited
Asthma
1 trial -
AVTX-002
Avalo Therapeutics
Non-Eosinophilic Asthma
1 trial -
Albuterol DPI 25 mcg/inh
Amphastar France Pharmaceuticals
Asthma
1 trial -
Albuterol HFA-BOI
Teva Pharma GmbH
Asthma
1 trial -
Amlitelimab, Placebo
Sanofi-aventis Healthcare Pty Ltd
Asthma
1 trial -
Antipyrine-benzocaine otic solution
United Therapeutics Europe Ltd
Asthma
1 trial -
Arm T1: Primatene Mist HFA
Amphastar France Pharmaceuticals
Asthma
1 trial -
Atuliflapon
AstraZeneca
Asthma
1 trial -
BI 671800
Boehringer Ingelheim
Asthma
1 trial -
Beclometasone
United Therapeutics Europe Ltd
Asthma
1 trial -
Beclomethasone dipropionate HFA
Teva Pharma GmbH
Asthma
1 trial -
Bronchodilator
Teva Pharma GmbH
Asthma
1 trial -
C4531029
Pfizer Australia Pty Ltd
Moderate-to-severe Asthma
1 trial -
CBP-201
S.L
Moderate to Severe Persistent Asthma
1 trial -
CHF6001 DPI
Chiesi Farmaceutici S.p.A
Asthma
1 trial -
CLI-05993AA9-01
Chiesi Farmaceutici S.p.A
Mild to moderate asthma
1 trial -
CQVM149C2201
Novartis Pharmaceuticals
Asthma
1 trial -
CSJ117
Novartis Pharmaceuticals
Asthma
2 trials -
D6830C00003
AstraZeneca AB
Asthma in adults who remain uncontrolled despite medium to high dose ICS plus LABA, and who are at risk of exacerbations.
1 trial -
D7552C00001
AstraZeneca AB
Moderate-to-Severe Uncontrolled Asthma
1 trial -
D8210C00003
AstraZeneca AB
Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
1 trial -
D8210C00005
AstraZeneca AB
Asthma
1 trial -
D9181C00002
AstraZeneca AB
Asthma
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.